Hudson Bay Capital Management
SBFM

Hudson Bay Capital Management’s Sunshine Biopharma SBFM Stock Holding History

Hudson Bay Capital Management’s Portfolio SBFM Stock Details SBFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-16
Closed -$720K – 1407
2022
Q1 		$720K Buy
+16
New +$779K 0.01% 856

Other funds holding SBFM

BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
DWM
Dakota Wealth Management Palm Beach Gardens, Florida $4.62B AUM 33.09% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Hudson Bay Capital Management's SBFM Position: Q2 2022 in Review

Hudson Bay Capital Management sold out of Sunshine Biopharma (SBFM) in Q2 2022, closing a stake of 16 shares — an estimated $720K sold.

Hudson Bay Capital Management first reported a position in SBFM in Q1 2022 and held it in 1 quarter. The position peaked at $720K in Q1 2022. 6 funds tracked by Wall St. Rank hold SBFM as of Q2 2022.

  • Hudson Bay Capital Management reported no remaining Sunshine Biopharma position as of Q2 2022 after selling out during the quarter.
  • Hudson Bay Capital Management sold 16 Sunshine Biopharma shares in Q2 2022, an estimated $720K.
  • Hudson Bay Capital Management first reported a position in Sunshine Biopharma in Q1 2022 and held it in 1 quarter.
  • Hudson Bay Capital Management's Sunshine Biopharma position peaked at $720K in Q1 2022.
  • 6 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2022.

Based on Hudson Bay Capital Management's 13F filing for Q2 2022, filed 12 Aug 2022.